Thrombocytosis

Thrombocytosis is a hematological disorder characterized by an abnormally elevated platelet count in the peripheral blood. In dogs and cats, the normal platelet count typically ranges from 150,000 to 400,000 platelets per microliter (µL) and 200,000 to 500,000 platelets/µL, respectively. Thrombocytosis is defined as a platelet count exceeding these reference intervals, often exceeding 600,000 to 1,000,000 platelets/µL. It is classified into two main types: primary (essential) thrombocythemia, a myeloproliferative neoplasm of megakaryocytic lineage, and secondary (reactive) thrombocytosis, which is more common and occurs as a response to various underlying conditions such as inflammation, iron deficiency, neoplasia, or splenic contraction. The clinical significance of thrombocytosis lies in its potential to cause thromboembolic complications, although in veterinary medicine, secondary thrombocytosis is often benign and resolves with treatment of the underlying cause. Accurate diagnosis and differentiation between primary and secondary forms are crucial for appropriate management and prognosis.

The etiology of thrombocytosis can be divided into primary and secondary causes. Primary thrombocytosis, also known as essential thrombocythemia, is a rare myeloproliferative neoplasm in dogs and cats, arising from clonal proliferation of megakaryocytes in the bone marrow. It is associated with mutations in genes such as JAK2, CALR, or MPL in humans, but similar mutations are not well-characterized in veterinary species. Secondary (reactive) thrombocytosis is far more common and results from increased production of thrombopoietin (TPO) or other cytokines that stimulate megakaryopoiesis. Causes include: 1) Inflammatory diseases: chronic infections, immune-mediated diseases (e.g., immune-mediated hemolytic anemia, polyarthritis), and systemic inflammatory response syndrome (SIRS). 2) Neoplasia: various tumors, especially lymphoma, mast cell tumors, and adenocarcinomas, which can produce cytokines like interleukin-6 (IL-6) that stimulate TPO production. 3) Iron deficiency anemia: leads to increased TPO production as a compensatory mechanism. 4) Splenic contraction or splenectomy: the spleen sequesters platelets, and its removal or contraction (e.g., due to excitement or exercise) can transiently increase platelet counts. 5) Acute blood loss or hemolysis: stimulates thrombopoiesis. 6) Drug-induced: corticosteroids, vincristine, and other chemotherapeutic agents can cause reactive thrombocytosis. 7) Endocrine disorders: hyperadrenocorticism (Cushing's syndrome) and hyperthyroidism in cats. 8) Physiologic stress: epinephrine release can cause splenic contraction and transient thrombocytosis.

Thrombocytosis is a common laboratory finding in dogs and cats, with secondary (reactive) thrombocytosis being the most frequent form. The prevalence varies depending on the population studied, but it is estimated that up to 30% of dogs with inflammatory or neoplastic diseases may exhibit thrombocytosis. There is no strong breed or sex predisposition for secondary thrombocytosis, as it reflects the underlying disease. However, primary thrombocytosis (essential thrombocythemia) is extremely rare and has been reported in a few cases in dogs, with no clear breed predilection. Age distribution follows the underlying cause: inflammatory and neoplastic conditions are more common in older animals, while infectious causes may affect younger animals. Geographic variation is related to the prevalence of specific infectious diseases (e.g., ehrlichiosis, leishmaniasis) that can cause inflammation and secondary thrombocytosis. In cats, thrombocytosis is less commonly reported than in dogs, but it can occur with chronic inflammatory diseases, neoplasia, or hyperthyroidism.

The pathophysiology of thrombocytosis involves an imbalance in platelet production, distribution, and destruction. In secondary (reactive) thrombocytosis, the primary mechanism is increased megakaryopoiesis driven by elevated levels of thrombopoietin (TPO) and other cytokines such as IL-6, IL-11, and erythropoietin. TPO is primarily produced by the liver and kidneys, and its production is upregulated in response to inflammation, iron deficiency, or tissue hypoxia. Inflammatory cytokines stimulate TPO production, leading to increased megakaryocyte proliferation and differentiation in the bone marrow, resulting in elevated platelet release. Iron deficiency anemia leads to increased TPO production as a compensatory response to stimulate erythropoiesis, which also stimulates megakaryopoiesis. Splenic contraction (e.g., due to epinephrine release) causes a shift of platelets from the splenic pool to the circulation, resulting in a transient increase in platelet count. Splenectomy removes the major site of platelet sequestration, leading to a persistent but usually mild thrombocytosis. In primary thrombocytosis (essential thrombocythemia), a clonal disorder of hematopoietic stem cells leads to autonomous proliferation of megakaryocytes, independent of TPO regulation. This results in persistently elevated platelet counts and an increased risk of thrombosis or hemorrhage due to platelet dysfunction. The clinical consequences of thrombocytosis are primarily related to the risk of thromboembolism, although in secondary forms, the risk is lower than in primary forms. Platelet function may be abnormal, leading to either prothrombotic or hemorrhagic tendencies.

Predisposing factors for secondary thrombocytosis include: 1) Chronic inflammatory diseases: e.g., inflammatory bowel disease, pancreatitis, dermatitis, pneumonia, and immune-mediated diseases. 2) Neoplastic conditions: especially those that produce cytokines, such as lymphoma, mast cell tumors, and various carcinomas. 3) Iron deficiency anemia: due to chronic blood loss (e.g., gastrointestinal bleeding, flea infestation) or nutritional deficiency. 4) Splenic disorders: splenectomy, splenic torsion, or functional hyposplenism. 5) Acute hemorrhage or hemolysis: stimulates compensatory thrombopoiesis. 6) Drug administration: corticosteroids, vincristine, and other chemotherapeutic agents. 7) Endocrine disorders: hyperadrenocorticism, hyperthyroidism. 8) Physiologic stress: excitement, exercise, or fear causing epinephrine release. 9) Infectious diseases: e.g., ehrlichiosis, leishmaniasis, and other chronic infections. For primary thrombocytosis, risk factors are largely genetic, but specific mutations have not been identified in veterinary species. Age may be a factor, as essential thrombocythemia is more common in older dogs.

Clinical signs of thrombocytosis are primarily related to the underlying cause, as secondary thrombocytosis itself is often asymptomatic. However, in some cases, especially with extreme thrombocytosis (platelet count > 1,000,000/µL), there may be an increased risk of thromboembolism, leading to signs such as acute lameness (due to limb ischemia), pulmonary thromboembolism (dyspnea, tachypnea), or neurological signs (seizures, ataxia) if cerebral vessels are affected. Conversely, some animals may exhibit bleeding tendencies due to platelet dysfunction, manifesting as petechiae, ecchymoses, or prolonged bleeding from wounds. In primary thrombocytosis, clinical signs may include lethargy, weakness, and signs related to thrombosis or hemorrhage. However, many animals with secondary thrombocytosis show signs of the underlying disease, such as fever, weight loss, anorexia, vomiting, diarrhea, or pallor. Physical examination may reveal splenomegaly (if splenic disease is present), lymphadenopathy (with neoplasia), or signs of inflammation (e.g., skin lesions, joint swelling). It is important to note that thrombocytosis is often an incidental finding on routine blood work, and clinical signs are usually those of the primary condition.

Differential diagnoses for thrombocytosis include: 1) Primary (essential) thrombocythemia: a myeloproliferative neoplasm; diagnosis requires persistent thrombocytosis without an identifiable underlying cause, and bone marrow examination shows megakaryocytic hyperplasia with atypical morphology. 2) Chronic inflammation: e.g., inflammatory bowel disease, pancreatitis, pneumonia; characterized by elevated inflammatory markers (e.g., C-reactive protein, globulins) and response to treatment of the underlying inflammation. 3) Iron deficiency anemia: microcytic hypochromic anemia with low serum iron, low ferritin, and high total iron-binding capacity; often due to chronic blood loss. 4) Neoplasia: especially lymphoma, mast cell tumors, and adenocarcinomas; diagnosis via imaging, cytology, or histopathology. 5) Splenic contraction or splenectomy: history of splenectomy or recent stress; platelet count usually normalizes after stress resolves. 6) Drug-induced: recent administration of corticosteroids, vincristine, or other drugs; platelet count returns to normal after drug discontinuation. 7) Endocrine disorders: hyperadrenocorticism (Cushing's syndrome) with characteristic clinical signs and abnormal adrenal function tests; hyperthyroidism in cats with elevated T4. 8) Acute blood loss or hemolysis: evidence of anemia, reticulocytosis, and history of hemorrhage or hemolysis. 9) Infectious diseases: e.g., ehrlichiosis, leishmaniasis; diagnosed via serology or PCR. 10) Physiologic stress: transient thrombocytosis due to epinephrine release; resolves with rest. To differentiate, a thorough history, physical examination, complete blood count, serum biochemistry, urinalysis, and additional tests such as iron panel, inflammatory markers, imaging, and bone marrow evaluation may be necessary.

The diagnostic approach to thrombocytosis should be systematic: 1) Confirm the thrombocytosis with a repeat CBC, ensuring that the sample was collected properly (avoiding platelet clumping, which can cause pseudothrombocytopenia). 2) Perform a thorough history and physical examination to identify any underlying disease. 3) Run a complete blood count with blood smear evaluation to assess platelet morphology and exclude clumping. 4) Perform serum biochemistry profile and urinalysis to evaluate for inflammatory, neoplastic, endocrine, or renal diseases. 5) If iron deficiency is suspected, measure serum iron, ferritin, and total iron-binding capacity. 6) If inflammation is suspected, measure acute-phase proteins (e.g., C-reactive protein, serum amyloid A) and consider imaging (radiography, ultrasonography) to identify inflammatory or neoplastic lesions. 7) If splenic disease is suspected, perform abdominal ultrasonography to evaluate splenic size and architecture. 8) If endocrine disease is suspected, perform adrenal function tests (ACTH stimulation test, low-dose dexamethasone suppression test) or thyroid hormone assays. 9) If primary thrombocytosis is suspected (persistent marked thrombocytosis without an underlying cause), consider bone marrow aspiration and biopsy to evaluate megakaryocytic hyperplasia and rule out myeloproliferative disorders. 10) In cases of suspected thromboembolism, perform imaging such as thoracic radiography, echocardiography, or CT angiography. The diagnostic algorithm should be tailored to the individual patient based on clinical findings and initial laboratory results.

Laboratory findings in thrombocytosis include: 1) Hematology: Elevated platelet count (>600,000/µL in dogs, >800,000/µL in cats). Blood smear may show large platelets (macrothrombocytes) or platelet clumps, which should be noted. Other CBC abnormalities may reflect the underlying cause, such as anemia (iron deficiency, hemolysis, blood loss), leukocytosis (inflammation), or leukopenia (viral infections). 2) Serum biochemistry: May reveal hyperglobulinemia (chronic inflammation), hypoalbuminemia (protein-losing enteropathy or nephropathy), elevated liver enzymes (hepatic disease), or elevated creatinine/BUN (renal disease). Iron panel may show low serum iron, low ferritin, and high TIBC in iron deficiency. 3) Urinalysis: May show proteinuria (if glomerular disease), hematuria (if urinary tract inflammation or neoplasia), or casts. 4) Blood gas analysis: May reveal metabolic acidosis or alkalosis depending on the underlying disease. 5) Specific biomarkers: C-reactive protein (CRP) may be elevated in inflammatory conditions; serum amyloid A (SAA) is an acute-phase protein; NT-proBNP may be elevated in cardiac disease; troponin I may be elevated in myocardial injury; SDMA is a renal biomarker; cPLI (canine pancreatic lipase immunoreactivity) for pancreatitis; fPLI for feline pancreatitis. 6) Serology/PCR: For infectious diseases such as Ehrlichia, Anaplasma, Leishmania, or FeLV/FIV. 7) Endocrinological assays: Cortisol levels (basal, ACTH stimulation test, low-dose dexamethasone suppression test) for hyperadrenocorticism; total T4 for hyperthyroidism. 8) Coagulation profile: May be normal, but in some cases, platelet function abnormalities may be present, and thromboelastography (TEG) may show hypercoagulability.

Imaging findings in thrombocytosis are primarily related to the underlying cause. 1) Radiography: Thoracic radiographs may reveal pulmonary infiltrates (pneumonia, neoplasia), cardiomegaly (if thromboembolism), or metastatic lesions. Abdominal radiographs may show splenomegaly, hepatomegaly, or masses. 2) Ultrasonography: Abdominal ultrasound is useful to evaluate splenic size and architecture (e.g., splenic torsion, neoplasia), liver appearance, adrenal gland size (hyperadrenocorticism), and to identify abdominal masses or lymphadenopathy. Doppler ultrasound can assess blood flow in vessels to detect thrombi. 3) Computed Tomography (CT): CT angiography is the gold standard for diagnosing pulmonary thromboembolism and can also detect other vascular thrombi. CT is also useful for staging neoplasia. 4) Magnetic Resonance Imaging (MRI): May be indicated for neurological signs to detect cerebral thromboembolism. 5) Echocardiography: To evaluate for heartworm disease, endocarditis, or intracardiac thrombi. 6) Endoscopy: May be used to investigate gastrointestinal bleeding (e.g., ulcers, neoplasia) that could cause iron deficiency anemia. 7) Fluoroscopy: Rarely used, but may be helpful in evaluating vascular dynamics. Imaging should be guided by clinical signs and suspected underlying disease.

Cytology and histopathology are essential for diagnosing the underlying cause of thrombocytosis. 1) Fine Needle Aspirates (FNA): FNA of enlarged lymph nodes, splenic masses, or other lesions can help diagnose neoplasia (e.g., lymphoma, mast cell tumor) or inflammation. Cytology of bone marrow aspirates is crucial for evaluating megakaryocyte numbers and morphology. In primary thrombocytosis, there is marked megakaryocytic hyperplasia with atypical megakaryocytes. In secondary thrombocytosis, megakaryocyte numbers may be increased but with normal morphology. 2) Fluid analysis: If effusions are present (e.g., pleural, peritoneal), analysis of the fluid (transudate vs. exudate, cell counts, cytology) can help identify inflammation, neoplasia, or other causes. 3) Histopathology: Biopsy of affected organs (e.g., liver, spleen, lymph node, bone marrow) provides a definitive diagnosis of the underlying disease. Bone marrow biopsy is particularly important to differentiate primary from secondary thrombocytosis. Histopathological features of essential thrombocythemia include hypercellular marrow with marked megakaryocytic proliferation, often with clustering and dysplasia. Special stains (e.g., reticulin stain) may show increased reticulin fibrosis in some cases. In secondary thrombocytosis, the marrow may show reactive changes, such as increased megakaryocytes but with normal maturation. Histopathology is also essential for diagnosing neoplasia, inflammatory diseases, or infectious agents (e.g., fungal organisms).

Treatment of thrombocytosis is primarily directed at the underlying cause. For secondary (reactive) thrombocytosis, no specific therapy is needed; the platelet count typically normalizes once the underlying condition is resolved. For example, treating infections with appropriate antimicrobials, managing inflammatory diseases with anti-inflammatory or immunosuppressive drugs, correcting iron deficiency with iron supplementation, or surgically removing neoplasms. In cases of splenic contraction, the platelet count returns to normal after the animal is rested. For primary (essential) thrombocythemia, treatment is aimed at reducing the risk of thromboembolism and controlling the platelet count. Options include: 1) Hydroxyurea: an antineoplastic agent that inhibits DNA synthesis, given orally at a dosage of 20-50 mg/kg once daily or every other day, adjusted to maintain platelet count below 600,000/µL. 2) Aspirin: low-dose antiplatelet therapy (0.5-5 mg/kg PO q24h) may be used to reduce thrombotic risk, but its use is controversial due to the risk of bleeding. 3) Anagrelide: a phosphodiesterase inhibitor that reduces platelet production, but its use in veterinary medicine is limited and not well-documented. 4) In severe cases, plateletpheresis may be considered, but it is rarely performed in veterinary practice. Supportive care includes monitoring for thromboembolic complications and managing any bleeding episodes. For all patients, it is important to address any concurrent conditions, such as dehydration, electrolyte imbalances, or anemia. The prognosis for secondary thrombocytosis is generally good if the underlying cause is treatable, while primary thrombocytosis carries a guarded prognosis due to the risk of thromboembolism and progression to myelofibrosis or acute leukemia.

The prognosis for thrombocytosis depends on the underlying cause. Secondary (reactive) thrombocytosis generally carries a good to excellent prognosis if the primary disease is treatable and resolves. For example, if thrombocytosis is due to a transient inflammatory condition or iron deficiency, the platelet count returns to normal with appropriate treatment, and the prognosis is excellent. However, if the underlying cause is a chronic or progressive disease such as neoplasia or severe inflammatory disease, the prognosis is guarded to poor, depending on the response to therapy. Primary (essential) thrombocythemia has a guarded prognosis due to the risk of thromboembolic events, which can be life-threatening. The median survival time in dogs with essential thrombocythemia is not well-defined, but with treatment, some dogs may survive for months to years. Negative prognostic indicators include the presence of thromboembolism, severe thrombocytosis (>1,000,000/µL), and lack of response to therapy. Regular monitoring is essential to detect complications early and adjust treatment accordingly.

Follow-up for thrombocytosis should be tailored to the underlying cause. For secondary thrombocytosis, recheck the platelet count at intervals appropriate for the primary disease. For example, after treating an infection, recheck the CBC in 2-4 weeks to confirm normalization. For chronic inflammatory or neoplastic diseases, regular monitoring of the platelet count and other parameters (e.g., inflammatory markers, tumor markers) is recommended. For primary thrombocytosis, more intensive monitoring is required: 1) Recheck platelet count every 1-2 weeks initially to assess response to therapy, then monthly once stable. 2) Monitor for signs of thromboembolism (e.g., acute lameness, dyspnea, neurological signs) and educate the owner to seek immediate veterinary care if these occur. 3) Perform periodic blood pressure measurements and urinalysis to monitor for hypertension and proteinuria, which may be associated with thromboembolic risk. 4) If on hydroxyurea, monitor CBC including white blood cell count and hematocrit to detect myelosuppression. 5) Consider repeat bone marrow evaluation if there is a change in clinical status or if the platelet count becomes refractory to treatment. Long-term management may include lifelong medication and regular veterinary visits every 3-6 months.

Pearls: 1) Always rule out platelet clumping as a cause of pseudothrombocytosis by examining a blood smear. 2) Secondary thrombocytosis is common and often benign; focus on finding the underlying cause. 3) Iron deficiency anemia is a common cause of thrombocytosis in dogs; consider gastrointestinal blood loss. 4) Splenic contraction due to stress can cause transient thrombocytosis; repeat the CBC after the animal is relaxed. 5) In cats, thrombocytosis is less common; consider hyperthyroidism or chronic inflammation. 6) If primary thrombocytosis is suspected, perform a bone marrow biopsy to confirm. 7) Low-dose aspirin may be beneficial in primary thrombocytosis to reduce thrombotic risk, but weigh the risk of bleeding. Pitfalls: 1) Failing to recognize that thrombocytosis is often a marker of an underlying disease and not treating the primary cause. 2) Misinterpreting a high platelet count as a primary disorder without investigating secondary causes. 3) Overlooking the possibility of thromboembolism in animals with extreme thrombocytosis. 4) Using aspirin in animals with bleeding tendencies or thrombocytopenia. 5) Not monitoring for myelosuppression when using hydroxyurea. 6) Assuming that thrombocytosis is always pathological; it can be a normal physiological response to stress.

Drug protocols for thrombocytosis are primarily for primary (essential) thrombocythemia and for managing thromboembolic risk. Based on Plumb's Veterinary Drug Handbook: 1) Hydroxyurea: Dogs: 20-50 mg/kg PO once daily or every other day, then adjust to maintain platelet count <600,000/µL. Cats: 10-20 mg/kg PO once daily, then adjust. Monitor CBC weekly initially, then monthly. Myelosuppression is a common adverse effect; reduce dose or discontinue if neutropenia or thrombocytopenia occurs. 2) Aspirin: Dogs: 0.5-5 mg/kg PO q24h. Cats: 5 mg (approximately 1/4 of a 81 mg tablet) PO q72h (due to slower elimination). Use with caution in animals with gastrointestinal ulcers, bleeding disorders, or concurrent corticosteroid use. 3) Anagrelide: Not commonly used in veterinary medicine; if used, dosage is extrapolated from human medicine: 0.5-1 mg PO q6-12h, but safety and efficacy are not well-established. 4) Clopidogrel: Dogs: 1-3 mg/kg PO q24h; Cats: 18.75 mg (1/4 of a 75 mg tablet) PO q24h. May be used as an alternative antiplatelet agent. 5) For secondary thrombocytosis, treatment is directed at the underlying cause. For example, iron supplementation for iron deficiency: Dogs: 100-300 mg elemental iron PO q24h; Cats: 50-100 mg PO q24h. For inflammation, use appropriate anti-inflammatory or immunosuppressive drugs (e.g., prednisone 0.5-2 mg/kg PO q24h, then taper). For infections, use appropriate antimicrobials based on culture and sensitivity. Always consider renal and hepatic function when dosing drugs, and monitor for drug interactions.

Evidence-based literature on thrombocytosis in veterinary medicine is limited, but several key studies and reviews provide guidance. A retrospective study by Stokol et al. (2000) evaluated thrombocytosis in dogs and found that secondary thrombocytosis was common, with inflammation and neoplasia being the most frequent causes. Another study by Neel et al. (2002) reported that iron deficiency anemia is a significant cause of thrombocytosis in dogs. A case series by Weiss (2005) described essential thrombocythemia in dogs, noting that it is rare and requires bone marrow evaluation for diagnosis. Consensus guidelines from the American College of Veterinary Internal Medicine (ACVIM) on the diagnosis and treatment of myeloproliferative disorders are not specific to thrombocytosis, but they emphasize the importance of differentiating primary from secondary causes. In terms of treatment, a study by Hammer et al. (1991) reported the use of hydroxyurea in dogs with essential thrombocythemia, showing efficacy in reducing platelet counts. However, there are no large randomized controlled trials. The use of aspirin in veterinary patients is based on extrapolation from human medicine, and its benefit in primary thrombocytosis is uncertain. Overall, the literature supports a diagnostic approach that focuses on identifying and treating the underlying cause, with specific therapy reserved for primary thrombocytosis.